Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences-Reference-Cited by-同舟云学术

Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences

Published:2020-02-01 Issue:2 Volume:30 Page:214-221
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Masaki Chie¹,Sugino Kiminori¹,Saito Naoko²,Akaishi Junko¹,Hames Kiyomi Y.¹,Tomoda Chisato¹,Suzuki Akifumi¹,Matsuzu Kenichi¹,Uruno Takashi¹,Ohkuwa Keiko¹,Kitagawa Wataru¹,Nagahama Mitsuji¹,Ito Koichi¹

Affiliation:

1. Department of Surgery, Ito Hospital, Tokyo, Japan.

2. Department of Diagnostic Radiology, International Medical Center, Saitama Medical University, Hidaka-City, Japan.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2019.0221

Reference29 articles.

1. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

2. Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma

3. Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell–Derived Thyroid Cancer

4. Management of recurrent or metastatic thyroid cancer

5. Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma [Review]

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial;Frontiers in Oncology;2024-07-30

2. Ten years’ real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer;Endocrine;2024-05-21

3. Effectiveness and safety of lenvatinib in a series of advanced well-differentiated thyroid carcinomas from a single tertiary cancer center and literature review;Minerva Endocrinology;2024-03

4. The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity;Supportive Care in Cancer;2023-11-29

5. Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm;European Thyroid Journal;2023-04-25